Findings

What do systematic reviews say?

256 questions · 278 findings · 34 reviews · ENT

Sort:Best matchNewest Highest certainty Download CSV

No studies found 86 · 30.9%GRADE not reported 1 · 0.4%Very low 88 · 31.7%Low 66 · 23.7%Moderate 35 · 12.6%High 2 · 0.7%

Positive pressure therapy vs placebo

Vertigo (frequency) · Ménière’s disease

1 finding from 1 review

Positive pressure therapy for Ménière's disease or syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Moderate

Positive pressure therapy vs placebo

VAS scores for vertigo after 8 weeks of treatment · Ménière’s disease

1 finding from 1 review

Positive pressure therapy for Ménière's disease or syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Moderate

Positive pressure therapy vs placebo

Loss or gain of hearing in 4 months (dB) · Ménière’s disease

1 finding from 1 review

Positive pressure therapy for Ménière's disease or syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 123 participants
Moderate

Positive pressure therapy vs placebo

Cumulative activity score · Ménière’s disease

1 finding from 1 review

Positive pressure therapy for Ménière's disease or syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 68 participants
Moderate

Positive pressure therapy vs placebo

Change in functional profile in the 8 weeks before and after 4 weeks of treatment · Ménière’s disease

1 finding from 1 review

Positive pressure therapy for Ménière's disease or syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Moderate

Positive pressure therapy vs placebo

Days of sick‐leave at 1 year · Ménière’s disease

1 finding from 1 review

Positive pressure therapy for Ménière's disease or syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 125 participants
Moderate

Capsaicin vs placebo

Overall nasal symptom score 36 weeks post‐treatment · non‐allergic rhinitis

1 finding from 1 review

Capsaicin for non‐allergic rhinitis 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Moderate

Capsaicin vs placebo

Treatment‐related adverse events · non‐allergic rhinitis

The review found no eligible studies for this question.

1 finding from 1 review

Capsaicin for non‐allergic rhinitis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Roxithromycin vs placebo

Patient response score Scale from: 1 to 6 · chronic rhinosinusitis in adults

1 finding from 1 review

Systemic antibiotics for chronic rhinosinusitis without nasal polyps in adults 2011 · Cochrane Headline outcomes only
no estimate extracted
1 study · 64 participants
Low

Roxithromycin vs placebo

Mean change from baseline of SNOT‐20 at the end of treatment Scale from: 0 to 5 · chronic rhinosinusitis in adults

1 finding from 1 review

Systemic antibiotics for chronic rhinosinusitis without nasal polyps in adults 2011 · Cochrane Headline outcomes only
no estimate extracted
1 study · 64 participants
Low

Roxithromycin vs placebo

Mean change from baseline of SNOT‐20 at 3 months post‐treatment Scale from: 0 to 5 · chronic rhinosinusitis in adults

1 finding from 1 review

Systemic antibiotics for chronic rhinosinusitis without nasal polyps in adults 2011 · Cochrane Headline outcomes only
no estimate extracted
1 study · 64 participants
Low

Corticosteroids vs placebo

Number of children with clinical adverse event: vertigo · Patients with idiopathic acute vestibular dysfunction (vestibular neuritis)

Corticosteroids showed no clear difference in vertigo compared with placebo (low certainty).

1 finding from 1 review

Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (vestibular neuritis) 2011 · Cochrane Headline outcomes only
RR 0.39 [0.04, 3.57]
2 studies · 60 participants
Low

Corticosteroids vs placebo

Dizziness Handicap Inventory score · Patients with idiopathic acute vestibular dysfunction (vestibular neuritis)

1 finding from 1 review

Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (vestibular neuritis) 2011 · Cochrane Headline outcomes only
no estimate extracted
1 study · 30 participants
Low

Corticosteroids vs placebo

Caloric extent of recovery (improvement as a % in lateralisation of electronystagmography on caloric testing) · Patients with idiopathic acute vestibular dysfunction (vestibular neuritis)

2 findings from 1 review

Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (vestibular neuritis) 2011 · Cochrane Headline outcomes only
no estimate extracted
1 study · 30 participants
Low
Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (vestibular neuritis) 2011 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 89 participants
Low

Corticosteroids vs placebo

Complete caloric recovery · Patients with idiopathic acute vestibular dysfunction (vestibular neuritis)

Corticosteroids may leads to higher complete caloric recovery compared with placebo (low certainty).

2 findings from 1 review

Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (vestibular neuritis) 2011 · Cochrane Headline outcomes only
RR 2.81 [1.32, 6]
2 studies · 50 participants
Low
Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (vestibular neuritis) 2011 · Cochrane Headline outcomes only
RR 1.58 [0.45, 5.62]
2 studies · 89 participants
Low

Corticosteroids vs placebo

Adverse effects · Patients with idiopathic acute vestibular dysfunction (vestibular neuritis)

1 finding from 1 review

Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (vestibular neuritis) 2011 · Cochrane Headline outcomes only
no estimate extracted
1 study · 73 participants
Moderate